Unknown

Dataset Information

0

Omentin protects H9c2 cells against docetaxel cardiotoxicity.


ABSTRACT:

Background

Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually in the spotlight due to its favourable effects on inflammation, glucose homeostasis and cardiovascular diseases. Also, recent data showed that in vitro anthracycline-induced cardiomyocyte apoptosis is counteracted by omentin suggesting its cardioprotective role.

Objective

Our aim was to evaluate omentin effects against docetaxel toxicity.

Results

Our data indicate that omentin inhibits docetaxel-induced viability loss and that increased viability is associated to decreased caspase-3 expression and cell death. Although omentin reduces NOX4 expression, it failed to reduce docetaxel-induced reactive oxygen species production. Our results indicate that omentin decreases docetaxel-induced endoplasmic reticulum stress, suggesting that cardioprotective role might be associated to ERS inhibition.

Conclusion

These data suggest that omentin treatment may contribute to decrease susceptibility to DTX-induced cardiotoxicity.

SUBMITTER: Lage R 

PROVIDER: S-EPMC6386316 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Omentin protects H9c2 cells against docetaxel cardiotoxicity.

Lage Ricardo R   Cebro-Márquez María M   Rodríguez-Mañero Moisés M   González-Juanatey José Ramón JR   Moscoso Isabel I  

PloS one 20190222 2


<h4>Background</h4>Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually in the spotlight due to its  ...[more]

Similar Datasets

| S-EPMC8406901 | biostudies-literature
| S-EPMC8603820 | biostudies-literature
| S-EPMC5551375 | biostudies-other
| S-EPMC7438920 | biostudies-literature
| S-EPMC4854406 | biostudies-literature
| S-EPMC6777440 | biostudies-literature
| S-EPMC6663922 | biostudies-literature
| S-EPMC8335840 | biostudies-literature
| S-EPMC2438979 | biostudies-other
| S-EPMC2239316 | biostudies-literature